View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
December 10, 2019updated 17 Mar 2022 5:02am

Futura’s DermaSys could enter market as medical device

Pharmaceutical company Futura Medical may be able to process its DermaSys technology through a medical devices regulatory path, following surprising results from the phase III clinical trial of its erectile dysfunction (ED) gel MED2005.

By Chloe Kent

Pharmaceutical company Futura Medical may be able to process its DermaSys technology through a medical devices regulatory path, following surprising results from the phase III clinical trial of its erectile dysfunction (ED) gel MED2005.

Free Report
img

Medical Device Industry Landscape In Asia-Pacific

GlobalData's APAC Medical Devices Industry Landscape – 2022 free study breaks down the APAC medical devices market by segment and region and includes insights on local and global competitors, pipeline product developments, clinical trials studies, and significant deals in the industry. The APAC medical device industry witnessed significant developments, launches, implementations, and adoption of new medical device technologies in the past decade, however the high cost of devices, regulatory hurdles, reimbursement pressure, and healthcare budget constraints have challenged market expansion across various territories and segments. APAC is the fastest growing regional market for medical device clinical trials, with China and Japan emerging as major clinical trial hotspots. The growth in medical device clinical trials in the APAC region is attributed to an increase in research partnerships between biopharma companies and clinical research organizations (CROs). This report also provides an in-depth analysis of the medical device market's opportunities and challenges, the influence of COVID-19 on the market, and government activities aimed to develop the APAC medical device market.
by GlobalData
Enter your details here to receive your free Report.

The company is working on developing a portfolio of products in the sexual health and pain management markets based on its transdermal DermaSys drug delivery technology. DermaSys enables targeted and rapid delivery of active pharmaceutical ingredients (APIs) through the skin to the required site of action.

In a phase III trial dubbed FM57, MED2005 showed strong efficacy, safety, speed of onset, and had a highly statistically significant impact on the participants in the control group of the experiment. Over 60% of participants saw onset within 10 minutes of applying of the gel.

However, the placebo used in the study also demonstrated statistically significant and clinically meaningful top line results, meaning that the study did not meet primary endpoints versus placebo.

The placebo did not contain glyceryl trinitrate (GTN), MED2005’s key ingredient, but did contain key ingredients that constitute DermaSys’ proven transdermal technology and was shown to be as effective in the treatment of ED as the active doses.

These results provide the company with a new, potentially simpler regulatory pathway for DermaSys as a medical device compared with MED2005 as a drug.

Futura Medical CEO James Barder said: “While we are surprised that FM57 has not met the primary endpoints versus placebo, we are excited that DermaSys alone has achieved such statistical significance in meeting all the primary endpoints against the baseline and key secondary endpoints using validated and globally accepted measurement tools. We now believe this supports the potential for a simpler route to regulatory approval for the proprietary DermaSys formulation as a clinically proven treatment for erectile dysfunction.

“We will provide shareholders with an update on what we believe will be a new simpler and expected lower-cost regulatory pathway as soon as possible.”

Related Companies

Free Report
img

Medical Device Industry Landscape In Asia-Pacific

GlobalData's APAC Medical Devices Industry Landscape – 2022 free study breaks down the APAC medical devices market by segment and region and includes insights on local and global competitors, pipeline product developments, clinical trials studies, and significant deals in the industry. The APAC medical device industry witnessed significant developments, launches, implementations, and adoption of new medical device technologies in the past decade, however the high cost of devices, regulatory hurdles, reimbursement pressure, and healthcare budget constraints have challenged market expansion across various territories and segments. APAC is the fastest growing regional market for medical device clinical trials, with China and Japan emerging as major clinical trial hotspots. The growth in medical device clinical trials in the APAC region is attributed to an increase in research partnerships between biopharma companies and clinical research organizations (CROs). This report also provides an in-depth analysis of the medical device market's opportunities and challenges, the influence of COVID-19 on the market, and government activities aimed to develop the APAC medical device market.
by GlobalData
Enter your details here to receive your free Report.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. The top stories of the day delivered to you every weekday. A weekly roundup of the latest news and analysis, sent every Friday. The medical device industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Medical Device Network